Total Payments
$785,842
2024 Payments
$148,101
Companies
67
Transactions
1,814
Medicare Patients
872
Medicare Billing
$116,720
Payment Breakdown by Category
Other$551,438 (70.2%)
Consulting$138,410 (17.6%)
Food & Beverage$48,277 (6.1%)
Travel$46,210 (5.9%)
Gifts$911.00 (0.1%)
Education$360.60 (0.0%)
Research$236.86 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $534,124 | 190 | 68.0% |
| Consulting Fee | $138,410 | 34 | 17.6% |
| Food and Beverage | $48,277 | 1,437 | 6.1% |
| Travel and Lodging | $46,210 | 126 | 5.9% |
| Honoraria | $17,300 | 7 | 2.2% |
| Gift | $911.00 | 2 | 0.1% |
| Education | $360.60 | 12 | 0.0% |
| Unspecified | $236.86 | 5 | 0.0% |
| Entertainment | $14.07 | 1 | 0.0% |
Payments by Type
General
$785,605
1,809 transactions
Research
$236.86
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| EMD Serono, Inc. | $219,894 | 250 | $0 (2024) |
| Biogen, Inc. | $194,816 | 276 | $0 (2024) |
| GENZYME CORPORATION | $194,363 | 271 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $48,058 | 244 | $0 (2024) |
| TG Therapeutics, Inc. | $29,560 | 51 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $20,925 | 21 | $0 (2024) |
| Horizon Therapeutics plc | $18,523 | 43 | $0 (2023) |
| Genentech USA, Inc. | $15,484 | 135 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $12,391 | 29 | $0 (2023) |
| Allergan, Inc. | $9,279 | 21 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $148,101 | 329 | EMD Serono, Inc. ($63,202) |
| 2023 | $129,700 | 321 | EMD Serono, Inc. ($79,020) |
| 2022 | $112,962 | 326 | EMD Serono, Inc. ($45,777) |
| 2021 | $88,189 | 262 | Biogen, Inc. ($35,905) |
| 2020 | $55,483 | 139 | Biogen, Inc. ($31,520) |
| 2019 | $127,701 | 227 | GENZYME CORPORATION ($59,383) |
| 2018 | $63,502 | 126 | GENZYME CORPORATION ($62,115) |
| 2017 | $60,204 | 84 | GENZYME CORPORATION ($55,370) |
All Payment Transactions
1,814 individual payment records from CMS Open Payments — Page 1 of 73
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,725.00 | General |
| Category: Neurology | ||||||
| 12/23/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,725.00 | General |
| Category: Neurology | ||||||
| 12/20/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,555.00 | General |
| Category: Neurology | ||||||
| 12/20/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,795.00 | General |
| Category: Neurology | ||||||
| 12/19/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $122.01 | General |
| Category: Neurology | ||||||
| 12/18/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $16.29 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/17/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $23.66 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/16/2024 | Biogen, Inc. | VUMERITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,055.00 | General |
| Category: Neurology | ||||||
| 12/16/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $21.76 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/12/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $78.58 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Biogen, Inc. | VUMERITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,055.00 | General |
| Category: Neurology | ||||||
| 12/10/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $8.43 | General |
| 12/09/2024 | Biogen, Inc. | VUMERITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,055.00 | General |
| Category: Neurology | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $684.03 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $212.19 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $124.99 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $50.12 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $50.12 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $31.39 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $30.48 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $26.54 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $26.54 | General |
| Category: Neuroscience | ||||||
| 12/05/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $17.86 | General |
| Category: Central Nervous System | ||||||
| 12/04/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $13.58 | General |
| Category: Neurology | ||||||
| 12/04/2024 | Biogen, Inc. | AVONEX (Biological), TYSABRI, VUMERITY | Food and Beverage | In-kind items and services | $5.54 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | SANOFI US SERVICES INC. | $236.86 | 5 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 195 | 240 | $111,814 | $30,208 |
| 2022 | 4 | 221 | 269 | $109,883 | $30,664 |
| 2021 | 8 | 266 | 349 | $131,990 | $36,402 |
| 2020 | 4 | 190 | 253 | $87,000 | $19,446 |
Total Patients
872
Total Services
1,111
Medicare Billing
$116,720
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 167 | 212 | $97,054 | $26,470 | 27.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $8,880 | $2,292 | 25.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 14 | 14 | $5,880 | $1,446 | 24.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 93 | 133 | $58,121 | $18,211 | 31.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 78 | 86 | $27,864 | $6,680 | 24.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 36 | 36 | $15,120 | $3,877 | 25.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 14 | 14 | $8,778 | $1,895 | 21.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 107 | 151 | $48,924 | $13,047 | 26.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 46 | 75 | $32,775 | $10,424 | 31.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 30 | 30 | $18,810 | $4,447 | 23.6% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2021 | 20 | 29 | $7,238 | $2,114 | 29.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 17 | 17 | $7,140 | $1,863 | 26.1% |
| 95910 | Nerve transmission studies, 7-8 studies | Office | 2021 | 13 | 13 | $7,670 | $1,851 | 24.1% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 20 | 21 | $6,573 | $1,723 | 26.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 13 | 13 | $2,860 | $933.49 | 32.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 121 | 167 | $54,108 | $11,617 | 21.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 25 | 29 | $12,673 | $3,433 | 27.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 25 | 25 | $15,675 | $3,316 | 21.2% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2020 | 19 | 32 | $4,544 | $1,080 | 23.8% |
About Dr. Amparo Gutierrez, MD
Dr. Amparo Gutierrez, MD is a Neurology healthcare provider based in Orlando, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1225051170.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amparo Gutierrez, MD has received a total of $785,842 in payments from pharmaceutical and medical device companies, with $148,101 received in 2024. These payments were reported across 1,814 transactions from 67 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($534,124).
As a Medicare-enrolled provider, Gutierrez has provided services to 872 Medicare beneficiaries, totaling 1,111 services with total Medicare billing of $116,720. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neuromuscular Medicine
- Location Orlando, FL
- Active Since 07/25/2006
- Last Updated 09/12/2024
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1225051170
Products in Payments
- AUBAGIO (Drug) $103,709
- Mavenclad (Drug) $101,609
- VUMERITY (Drug) $93,982
- LEMTRADA (Drug) $80,417
- MAVENCLAD (Drug) $78,188
- TYSABRI (Biological) $42,005
- MAYZENT (Drug) $31,401
- TECFIDERA (Drug) $30,113
- BRIUMVI (Drug) $29,560
- ZEPOSIA (Drug) $24,484
- UPLIZNA (Drug) $18,523
- KESIMPTA (Drug) $13,687
- UBRELVY (Drug) $9,487
- Ponvory (Drug) $9,250
- OCREVUS (Biological) $8,192
- Ocrevus (Biological) $7,114
- Radicava (Drug) $4,639
- BAFIERTAM (Drug) $995.27
- GILENYA (Drug) $994.96
- ULTOMIRIS (Biological) $830.51
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Orlando
Dr. Ramon Rodriguez-Cruz, Md, MD
Neurology — Payments: $1.6M
Neurology $1.6M
Mark Klafter, D.o, D.O
Neurology — Payments: $272,905
Neurology $272,905
Dr. Nicholas Avgeropoulos, Md, MD
Neurology — Payments: $161,837
Neurology $161,837
Dr. Herbert Newton, M.d, M.D
Neurology — Payments: $105,226
Neurology $105,226
Mr. Danish Bhatti, Mbbs, MBBS
Neurology — Payments: $93,560
Neurology $93,560
Fernando Gonzales-Portillo, Md, MD
Neurology — Payments: $42,248
Neurology $42,248